Top

Published in:

01-04-2010 | Review

Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics

Authors: Gabor G. Kovacs, Gergő Botond, Herbert Budka

Published in: Acta Neuropathologica | Issue 4/2010

Abstract

Neuropathological diagnosis of neurodegenerative dementias evolved by adapting the results of neuroanatomy, biochemistry, and cellular and molecular biology. Milestone findings of intra- and extracellular argyrophilic structures, visualizing protein deposition, initiated a protein-based classification. Widespread application of immunohistochemical and biochemical investigations revealed that (1) there are modifications of proteins intrinsic to disease (species that are phosphorylated, nitrated, oligomers, proteinase-resistant, with or without amyloid characteristics; cleavage products), (2) disease forms characterized by the accumulation of a single protein only are rather the exception than the rule, and (3) some modifications of proteins elude present neuropathological diagnostic procedures. In this review, we summarize how neuropathology, together with biochemistry, contributes to disease typing, by demonstrating a spectrum of disorders characterized by the deposition of various modifications of various proteins in various locations. Neuropathology may help to elucidate how brain pathologies alter the detectability of proteins in body fluids by upregulation of physiological forms or entrapment of different proteins. Modifications of at least the five most relevant proteins (amyloid-β, prion protein, tau, α-synuclein, and TDP-43), aided by analysis of further “attracted” proteins, are pivotal to be evaluated simultaneously with different methods. This should complement the detection of biomarkers associated with pathogenetic processes, and also neuroimaging and genetic analysis, in order to obtain a highly personalized diagnostic profile. Defining clusters of patients based on the patterns of protein deposition and immunohistochemically or biochemically detectable modifications of proteins (“codes”) may have higher prognostic predictive value, may be useful for monitoring therapy, and may open new avenues for research on pathogenesis.

Alafuzoff I, Pikkarainen M, Al-Sarraj S et al (2006) Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 65:740–757PubMed

Anderson JM, Hampton DW, Patani R et al (2008) Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 131:1736–1748PubMed

Anderson JM, Patani R, Reynolds R et al (2009) Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol 117:583–589PubMed

Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752PubMed

Andreadis A, Brown WM, Kosik KS (1992) Structure and novel exons of the human tau gene. Biochemistry 31:10626–10633PubMed

Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC (2004) Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson’s disease. FASEB J 18:932–934PubMed

Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111:529–538PubMed

Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611PubMed

Arai T, Mackenzie IR, Hasegawa M et al (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136PubMed

10.

Armstrong RA, Lantos PL, Cairns NJ (2005) Overlap between neurodegenerative disorders. Neuropathology 25:111–124PubMed

11.

Armstrong RA, Lantos PL, Cairns NJ (2008) What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathology 28:351–365PubMed

12.

Bancher C, Brunner C, Lassmann H et al (1989) Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles. Prog Clin Biol Res 317:837–848PubMed

13.

Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE (2002) Pathway complexity of prion protein assembly into amyloid. J Biol Chem 277:21140–21148PubMed

14.

Beyer K, Domingo-Sabat M, Ariza A (2009) Molecular pathology of Lewy body diseases. Int J Mol Sci 10:724–745PubMed

15.

Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, Ariza A (2008) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9:15–23PubMed

16.

Bibl M, Mollenhauer B, Esselmann H et al (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMed

17.

Bibl M, Mollenhauer B, Lewczuk P et al (2007) Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 12:671–680PubMed

18.

Bigio EH, Lipton AM, Yen SH et al (2001) Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J Neuropathol Exp Neurol 60:328–341PubMed

19.

Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer’s disease. Biochim Biophys Acta 1739:216–223PubMed

20.

Borroni B, Malinverno M, Gardoni F et al (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71:1796–1803PubMed

21.

Braak E, Braak H, Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87:554–567PubMed

22.

Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130PubMed

23.

Buee-Scherrer V, Buee L, Leveugle B et al (1997) Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer’s disease and other neurodegenerative disorders. Ann Neurol 42:356–359PubMed

24.

Cairns NJ, Bigio EH, Mackenzie IR et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5–22PubMed

25.

Cairns NJ, Neumann M, Bigio EH et al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240PubMed

26.

Campbell BC, McLean CA, Culvenor JG et al (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease. J Neurochem 76:87–96PubMed

27.

Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134–138PubMed

28.

Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383:685–690PubMed

29.

Cupidi C, Capobianco R, Goffredo D et al (2010) Neocortical Variation of Abeta Load in Fully Expressed, Pure Alzheimer’s Disease. J Alzheimers Dis 19:57–68PubMed

30.

Dalfo E, Martinez A, Muntane G, Ferrer I (2006) Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick’s disease. Neurosci Lett 400:125–129PubMed

31.

Danielson SR, Held JM, Schilling B, Oo M, Gibson BW, Andersen JK (2009) Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson’s disease. Anal Chem 81:7823–7828PubMed

32.

Davidson Y, Amin H, Kelley T et al (2009) TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathol 118:359–369PubMed

33.

Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5:347–354PubMed

34.

Derkinderen P, Scales TM, Hanger DP et al (2005) Tyrosine 394 is phosphorylated in Alzheimer’s paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci 25:6584–6593PubMed

35.

Dickson DW (1999) Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 246(Suppl 2):II6–II15PubMed

36.

Dickson DW, Fujishiro H, DelleDonne A et al (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444PubMed

37.

Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118:5–36PubMed

38.

Englund H, Degerman Gunnarsson M et al (2009) Oligomerization partially explains the lowering of Abeta42 in Alzheimer’s disease cerebrospinal fluid. Neurodegener Dis 6:139–147PubMed

39.

Feany MB, Mattiace LA, Dickson DW (1996) Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol 55:53–67PubMed

40.

Ferrer I, Blanco R, Carmona M et al (2001) Prion protein expression in senile plaques in Alzheimer’s disease. Acta Neuropathol 101:49–56PubMed

41.

Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F (1991) Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol 81:591–596PubMed

42.

Foulds PG, Davidson Y, Mishra M et al (2009) Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol 118(5):647–658

43.

Frank S, Tolnay M (2009) Frontotemporal lobar degeneration: toward the end of conFUSion. Acta Neuropathol 118:629–631PubMed

44.

Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP (2008) TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67:62–67PubMed

45.

Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW (2008) Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies. Acta Neuropathol 116:17–24PubMed

46.

Fujishiro H, Uchikado H, Arai T et al (2009) Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 117:151–158PubMed

47.

Fujita K, Ito H, Nakano S, Kinoshita Y, Wate R, Kusaka H (2008) Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease. Acta Neuropathol 116:439–445PubMed

48.

Fujiwara H, Hasegawa M, Dohmae N et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164PubMed

49.

Gambetti P, Dong Z, Yuan J et al (2008) A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 63:697–708PubMed

50.

Geser F, Martinez-Lage M, Kwong LK, Lee VM, Trojanowski JQ (2009) Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol 256:1205–1214PubMed

51.

Geser F, Martinez-Lage M, Robinson J et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66:180–189PubMed

52.

Geser F, Winton MJ, Kwong LK et al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133–145PubMed

53.

Ghetti B, Tagliavini F, Takao M, Bugiani O, Piccardo P (2003) Hereditary prion protein amyloidoses. Clin Lab Med 23:65–85 viiiPubMed

54.

Giaccone G, Mangieri M, Capobianco R et al (2008) Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiol Aging 29:1864–1873PubMed

55.

Giaccone G, Marcon G, Mangieri M et al (2008) Atypical tauopathy with massive involvement of the white matter. Neuropathol Appl Neurobiol 34:468–472PubMed

56.

Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985–989PubMed

57.

Giasson BI, Lee VM, Trojanowski JQ (2003) Interactions of amyloidogenic proteins. Neuromolecular Med 4:49–58PubMed

58.

Goedert M, Jakes R, Crowther RA et al (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer’s disease: identification of phosphorylation sites in tau protein. Biochem J 301(Pt 3):871–877PubMed

59.

Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526PubMed

60.

Good PF, Werner P, Hsu A, Olanow CW, Perl DP (1996) Evidence of neuronal oxidative damage in Alzheimer’s disease. Am J Pathol 149:21–28PubMed

61.

Graeber MB (2009) Biomarkers for Parkinson’s disease. Exp Neurol 216:249–253PubMed

62.

Guillozet-Bongaarts AL, Glajch KE et al (2007) Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol 113:513–520PubMed

63.

Haik S, Privat N, Adjou KT et al (2002) Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol 103:516–520PubMed

64.

Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H (1998) Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 96:116–122PubMed

65.

Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112–119PubMed

66.

Hanger DP, Byers HL, Wray S et al (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282:23645–23654PubMed

67.

Hart GW (1997) Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem 66:315–335PubMed

68.

Hasegawa M, Arai T, Akiyama H et al (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130:1386–1394PubMed

69.

Hasegawa M, Arai T, Nonaka T et al (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64:60–70PubMed

70.

He W, Barrow CJ (1999) The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 38:10871–10877PubMed

71.

Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18:8126–8132PubMed

72.

Higashi S, Iseki E, Yamamoto R et al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294PubMed

73.

Hill AF, Joiner S, Wadsworth JD et al (2003) Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126:1333–1346PubMed

74.

Hishikawa N, Hashizume Y, Yoshida M, Niwa J, Tanaka F, Sobue G (2005) Tuft-shaped astrocytes in Lewy body disease. Acta Neuropathol 109:373–380PubMed

75.

Hodara R, Norris EH, Giasson BI et al (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279:47746–47753PubMed

76.

Hoffmann R, Lee VM, Leight S, Varga I, Otvos L Jr (1997) Unique Alzheimer’s disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry 36:8114–8124PubMed

77.

Horiguchi T, Uryu K, Giasson BI et al (2003) Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 163:1021–1031PubMed

78.

Horvath J, Kovari E, Bouras C, Burkhard PR (2009) Neuropathological correlates of lower limb corticobasal degeneration. Neuropathol Appl Neurobiol 35:623–627PubMed

79.

Hu WT, Josephs KA, Knopman DS et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 116:215–220PubMed

80.

Ichihara K, Uchihara T, Nakamura A, Suzuki Y, Mizutani T (2009) Selective deposition of 4-repeat tau in cerebral infarcts. J Neuropathol Exp Neurol 68:1029–1036PubMed

81.

Igaz LM, Kwong LK, Xu Y et al (2008) Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 173:182–194PubMed

82.

Iqbal K, Flory M, Khatoon S et al (2005) Subgroups of Alzheimer’s disease based on cerebrospinal fluid molecular markers. Ann Neurol 58:748–757PubMed

83.

Isaacs AM, Powell C, Webb TE, Linehan JM, Collinge J, Brandner S (2008) Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. Neuropathol Appl Neurobiol 34:446–456PubMed

84.

Iseki E, Marui W, Kosaka K, Ueda K (1999) Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 265:9–12PubMed

85.

Iseki E, Togo T, Suzuki K et al (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 105:265–270PubMed

86.

Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMed

87.

Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45–53PubMed

88.

Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ (1996) Full-length amyloid-beta (1–42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol 149:1823–1830PubMed

89.

Jellinger KA (2009) Absence of alpha-synuclein pathology in postencephalitic parkinsonism. Acta Neuropathol 118:371–379PubMed

90.

Jellinger KA (2009) Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp? Acta Neuropathol 117:101–110PubMed

91.

Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235PubMed

92.

Jellinger KA (2007) More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol 114:299–303PubMed

93.

Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm 116:1111–1162PubMed

94.

Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257:80–87PubMed

95.

Jendroska K, Poewe W, Daniel SE et al (1995) Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 90:461–466PubMed

96.

Josephs KA, Katsuse O, Beccano-Kelly DA et al (2006) Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 65:396–405PubMed

97.

Josephs KA, Stroh A, Dugger B, Dickson DW (2009) Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol 118:349–358PubMed

98.

Josephs KA, Whitwell JL, Parisi JE et al (2008) Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol Aging 29:566–573PubMed

99.

Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 100:2047–2052PubMed

100.

Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K (2009) Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 29:566–573PubMed

101.

Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 67:155–161PubMed

102.

Kalaitzakis ME, Pearce RK (2009) The morbid anatomy of dementia in Parkinson’s disease. Acta Neuropathol 118:587–598PubMed

103.

Kasai T, Tokuda T, Ishigami N et al (2009) Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 117:55–62PubMed

104.

Kasai T, Tokuda T, Yamaguchi N et al (2008) Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci Lett 436:52–56PubMed

105.

Kim EJ, Sung JY, Lee HJ et al (2006) Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem 281:33250–33257PubMed

106.

Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268:24374–24384PubMed

107.

Kovacs GG, Alafuzoff I, Al-Sarraj S et al (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 26:343–350PubMed

108.

Kovacs GG, Budka H (2009) Molecular pathology of human prion diseases. Int J Mol Sci 10:976–999PubMed

109.

Kovacs GG, Budka H (2009) Protein-based neuropathology and molecular classification of human neurodegenerative diseases. In: Ovadi J, Orosz F (eds) Protein folding and misfolding: neurodegenerative diseases. Springer, the Netherlands, pp 251–272

110.

Kovacs GG, Gelpi E, Ströbel T et al (2007) Involvement of the endosomal-lysosomal system correlates with regional pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 66:628–636PubMed

111.

Kovacs GG, Majtenyi K, Spina S et al (2008) White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 67:963–975PubMed

112.

Kovacs GG, Milenkovic IJ, Preusser M, Budka H (2008) Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord 23:1608–1612PubMed

113.

Kovacs GG, Zerbi P, Voigtlander T et al (2002) The prion protein in human neurodegenerative disorders. Neurosci Lett 329:269–272PubMed

114.

Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405–1410PubMed

115.

Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62:1241–1253PubMed

116.

Kwiatkowski TJ Jr, Bosco DA, Leclerc AL et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208PubMed

117.

Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453PubMed

118.

Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:1128–1132PubMed

119.

Layfield R, Lowe J, Bedford L (2005) The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem 41:157–171PubMed

120.

Lee G, Neve RL, Kosik KS (1989) The microtubule binding domain of tau protein. Neuron 2:1615–1624PubMed

121.

Lee G, Thangavel R, Sharma VM et al (2004) Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci 24:2304–2312PubMed

122.

Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159PubMed

123.

Lefebvre T, Ferreira S, Dupont-Wallois L et al (2003) Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins—a role in nuclear localization. Biochim Biophys Acta 1619:167–176PubMed

124.

Leverenz JB, Umar I, Wang Q et al (2007) Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol 17:139–145PubMed

125.

Lindboe CF, Hansen HB (1998) The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 17:204–209PubMed

126.

Lindner H, Helliger W (2001) Age-dependent deamidation of asparagine residues in proteins. Exp Gerontol 36:1551–1563PubMed

127.

Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 280:22670–22678PubMed

128.

Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA 101:10804–10809PubMed

129.

Lu JQ, Fan Y, Mitha AP, Bell R, Metz L, Moore GR, Yong VW (2009) Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions. J Neuropathol Exp Neurol 68:179–189PubMed

130.

Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. J Alzheimers Dis 12:365–375PubMed

131.

Mackenzie IR, Neumann M, Bigio EH et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4PubMed

132.

Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR (2006) Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63:38–46PubMed

133.

Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245–4249PubMed

134.

Mateen FJ, Josephs KA (2009) TDP-43 is not present in brain tissue of patients with schizophrenia. Schizophr Res 108:297–298PubMed

135.

McKee AC, Cantu RC, Nowinski CJ et al (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68:709–735PubMed

136.

Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM (1996) Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer’s disease. Acta Neuropathol 91:633–641PubMed

137.

Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R (2009) Tau oligomers and aggregation in Alzheimer disease. J Neurochem. doi:JNC6511[pii]10.1111/j.1471-4159.2009.06511.x

138.

Meyne F, Gloeckner SF, Ciesielczyk B et al (2009) Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis. doi:12G39G6736J3K264[pii]10.3233/JAD-2009-1110

139.

Miki Y, Mori F, Hori E, Kaimori M, Wakabayashi K (2009) Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol 117:713–718PubMed

140.

Mikolaenko I, Pletnikova O, Kawas CH et al (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 64:156–162PubMed

141.

Miller DW, Cookson MR, Dickson DW (2004) Glial cell inclusions and the pathogenesis of neurodegenerative diseases. Neuron Glia Biol 1:13–21PubMed

142.

Mondragon-Rodriguez S, Mena R, Binder LI, Smith MA, Perry G, Garcia-Sierra F (2008) Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology. Neuropathol Appl Neurobiol 34:62–75PubMed

143.

Mori F, Hayashi S, Yamagishi S et al (2002) Pick’s disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus. Acta Neuropathol 104:455–461PubMed

144.

Morishima-Kawashima M, Hasegawa M, Takio K et al (1995) Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270:823–829PubMed

145.

Munoz DG, Neumann M, Kusaka H et al (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118:617–627PubMed

146.

Muntane G, Dalfo E, Martinez A, Ferrer I (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related alpha-synucleinopathies. Neuroscience 152:913–923PubMed

147.

Murray IV, Giasson BI, Quinn SM et al (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42:8530–8540PubMed

148.

Nakamura T, Yamashita H, Takahashi T, Nakamura S (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun 280:1085–1092PubMed

149.

Nakashima-Yasuda H, Uryu K, Robinson J et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221–229PubMed

150.

Naslund J, Schierhorn A, Hellman U et al (1994) Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 91:8378–8382PubMed

151.

Negro A, Brunati AM, Donella-Deana A, Massimino ML, Pinna LA (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J 16:210–212PubMed

152.

Nemes Z, Devreese B, Steinert PM, Van Beeumen J, Fesus L (2004) Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer’s neurofibrillary tangles. FASEB J 18:1135–1137PubMed

153.

Nemes Z, Petrovski G, Aerts M, Sergeant K, Devreese B, Fesus L (2009) Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies. J Biol Chem 284:27252–27264PubMed

154.

Neumann M, Kahle PJ, Giasson BI et al (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110:1429–1439PubMed

155.

Neumann M, Kwong LK, Lee EB et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117:137–149PubMed

156.

Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931PubMed

157.

Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616PubMed

158.

Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133PubMed

159.

Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA (1986) Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 387:271–280PubMed

160.

Newman J, Rissman RA, Sarsoza F et al (2005) Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol 110:135–144PubMed

161.

Norlund MA, Lee JM, Zainelli GM, Muma NA (1999) Elevated transglutaminase-induced bonds in PHF tau in Alzheimer’s disease. Brain Res 851:154–163PubMed

162.

Obi K, Akiyama H, Kondo H et al (2008) Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 210:409–420PubMed

163.

Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69:3584–3596PubMed

164.

Paleologou KE, Kragh CL, Mann DM et al (2009) Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132:1093–1101PubMed

165.

Paleologou KE, Schmid AW, Rospigliosi CC et al (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283:16895–16905PubMed

166.

Papadopoulos D, Ewans L, Pham-Dinh D, Knott J, Reynolds R (2006) Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. Mol Cell Neurosci 31:597–612PubMed

167.

Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79–100PubMed

168.

Parchi P, Castellani R, Capellari S et al (1996) Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39:767–778PubMed

169.

Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233PubMed

170.

Parchi P, Strammiello R, Notari S et al. (2009) Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrP(Sc) types: an updated classification. Acta Neuropathol 118:659–671

171.

Parkin ET, Watt NT, Hussain I et al (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. Proc Natl Acad Sci USA 104:11062–11067PubMed

172.

Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMed

173.

Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMed

174.

Pennington C, Chohan G, Mackenzie J et al (2009) The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Neurosci Lett 455:56–59PubMed

175.

Petersen RC, Parisi JE, Dickson DW et al (2006) Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665–672PubMed

176.

Piao YS, Tan CF, Iwanaga K et al (2005) Sporadic four-repeat tauopathy with frontotemporal degeneration, parkinsonism and motor neuron disease. Acta Neuropathol 110:600–609PubMed

177.

Popescu A, Lippa CF, Lee VM, Trojanowski JQ (2004) Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 61:1915–1919PubMed

178.

Powers JM, Byrne NP, Ito M et al (2003) A novel leukoencephalopathy associated with tau deposits primarily in white matter glia. Acta Neuropathol 106:181–187PubMed

179.

Puig B, Rey MJ, Ferrer I (2005) Individual and regional variations of phospho-tau species in progressive supranuclear palsy. Acta Neuropathol 110:261–268PubMed

180.

Quilty MC, King AE, Gai WP et al (2006) Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol 199:249–256PubMed

181.

Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM (2005) Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15:16R–28RPubMed

182.

Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362PubMed

183.

Reyes JF, Reynolds MR, Horowitz PM et al (2008) A possible link between astrocyte activation and tau nitration in Alzheimer’s disease. Neurobiol Dis 31:198–208PubMed

184.

Reynolds CH, Garwood CJ, Wray S et al (2008) Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 283:18177–18186PubMed

185.

Reynolds MR, Berry RW, Binder LI (2005) Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer’s disease. Biochemistry 44:1690–1700PubMed

186.

Reynolds MR, Reyes JF, Fu Y et al (2006) Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer’s disease and other tauopathies. J Neurosci 26:10636–10645PubMed

187.

Rhein V, Song X, Wiesner A et al (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci USA 106:20057–20062PubMed

188.

Roher AE, Lowenson JD, Clarke S et al (1993) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J Biol Chem 268:3072–3083PubMed

189.

Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 61:1916–1926PubMed

190.

Safar J, Wille H, Itri V et al (1998) Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med 4:1157–1165PubMed

191.

Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 215:173–176PubMed

192.

Saito Y, Kawashima A, Ruberu NN et al (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMed

193.

Saito Y, Murayama S (2007) Neuropathology of mild cognitive impairment. Neuropathology 27:578–584PubMed

194.

Saito Y, Ruberu NN, Sawabe M et al (2004) Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63:911–918PubMed

195.

Santpere G, Ferrer I (2009) Delineation of early changes in cases with progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation. Brain Pathol 19:177–187PubMed

196.

Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69:2197–2204PubMed

197.

Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66:200–208PubMed

198.

Sergeant N, Bombois S, Ghestem A et al (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem 85:1581–1591PubMed

199.

Sergeant N, Delacourte A, Buee L (2005) Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739:179–197PubMed

200.

Sergeant N, Wattez A, Delacourte A (1999) Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively “exon 10” isoforms. J Neurochem 72:1243–1249PubMed

201.

Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6:295–303PubMed

202.

Shimizu H, Kakita A, Takahashi H (2008) Spinal cord tau pathology in cervical spondylotic myelopathy. Acta Neuropathol 115:185–192PubMed

203.

Shimura H, Schlossmacher MG, Hattori N et al (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293:263–269PubMed

204.

Silveira-Moriyama L, Gonzalez AM, O’Sullivan SS et al (2009) Concomitant progressive supranuclear palsy and multiple system atrophy: more than a simple twist of fate? Neurosci Lett 467:208–211PubMed

205.

Singer SM, Zainelli GM, Norlund MA, Lee JM, Muma NA (2002) Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer’s disease. Neurochem Int 40:17–30PubMed

206.

Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 17:2653–2657PubMed

207.

Snow AD, Mar H, Nochlin D et al (1990) Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer’s disease and Down’s syndrome. Am J Pathol 137:1253–1270PubMed

208.

Song YJ, Halliday GM, Holton JL et al (2009) Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol 68:1073–1083PubMed

209.

Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65:184–189PubMed

210.

Takahashi M, Tsujioka Y, Yamada T et al (1999) Glycosylation of microtubule-associated protein tau in Alzheimer’s disease brain. Acta Neuropathol 97:635–641PubMed

211.

Tan CF, Piao YS, Kakita A et al (2005) Frontotemporal dementia with co-occurrence of astrocytic plaques and tufted astrocytes, and severe degeneration of the cerebral white matter: a variant of corticobasal degeneration? Acta Neuropathol 109:329–338PubMed

212.

Tekirian TL, Saido TC, Markesbery WR et al (1998) N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol 57:76–94PubMed

213.

Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredici K, Braak H (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61:282–293PubMed

214.

Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800PubMed

215.

Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405–44411PubMed

216.

Tolnay M, Clavaguera F (2004) Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 24:269–283PubMed

217.

Trojanowski JQ, Lee VM (2000) “Fatal attractions” of proteins. A comprehensive hypothetical mechanism underlying Alzheimer’s disease and other neurodegenerative disorders. Ann N Y Acad Sci 924:62–67PubMedCrossRef

218.

Trojanowski JQ, Mattson MP (2003) Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses. Neuromolecular Med 4:1–6PubMed

219.

Tsuboi Y, Ahlskog JE, Apaydin H, Parisi JE, Dickson DW (2001) Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls. Neurology 57:1675–1678PubMed

220.

Uchikado H, DelleDonne A, Ahmed Z, Dickson DW (2006) Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol 65:387–395PubMed

221.

Uchikado H, DelleDonne A, Uitti R, Dickson DW (2006) Coexistence of PSP and MSA: a case report and review of the literature. Acta Neuropathol 111:186–192PubMed

222.

Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65:685–697PubMed

223.

Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564PubMed

224.

Uversky VN, Oldfield CJ, Midic U et al (2009) Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics 10(Suppl 1):S7PubMed

225.

Uversky VN, Yamin G, Munishkina LA et al (2005) Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res Mol Brain Res 134:84–102PubMed

226.

Vance C, Rogelj B, Hortobagyi T et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211PubMed

227.

Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH (2005) Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res Mol Brain Res 138:135–144PubMed

228.

Vemuri P, Wiste HJ, Weigand SD et al (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73:294–301PubMed

229.

Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol 99:14–20PubMed

230.

Wakabayashi K, Kawachi I, Toyoshima Y, Takahashi H (1999) Occurrence of argyrophilic grains in multiple system atrophy: histopathological examination of 26 autopsy cases. No To Shinkei 51:433–437PubMed

231.

Wakabayashi K, Takahashi H (2006) Cellular pathology in multiple system atrophy. Neuropathology 26:338–345PubMed

232.

Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27:494–506PubMed

233.

Wang JZ, Grundke-Iqbal I, Iqbal K (1996) Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer’s disease. Nat Med 2:871–875PubMed

234.

Wang Q, Woltjer RL, Cimino PJ, Pan C, Montine KS, Zhang J, Montine TJ (2005) Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 19:869–871PubMed

235.

Wang Z, Udeshi ND, O’Malley M, Shabanowitz J, Hunt DF, Hart GW (2009) Enrichment and site-mapping of O-Linked N-Acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation (ETD) mass spectrometry. Mol Cell Proteomics (in press)

236.

Watanabe A, Hong WK, Dohmae N, Takio K, Morishima-Kawashima M, Ihara Y (2004) Molecular aging of tau: disulfide-independent aggregation and non-enzymatic degradation in vitro and in vivo. J Neurochem 90:1302–1311PubMed

237.

Watanabe A, Takio K, Ihara Y (1999) Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J Biol Chem 274:7368–7378PubMed

238.

Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG (2008) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64:239–246PubMed

239.

Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T (2007) Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 130:1566–1576PubMed

240.

Wiltfang J, Esselmann H, Smirnov A et al (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54:263–267PubMed

241.

Wirths O, Weickert S, Majtenyi K et al (2000) Lewy body variant of Alzheimer’s disease: alpha-synuclein in dystrophic neurites of A beta plaques. Neuroreport 11:3737–3741PubMed

242.

Woulfe J, Gray DA, Mackenzie IR (2009) FUS-immunoreactive intranuclear inclusions in neurodegenerative disease. Brain Pathol. doi:BPA337[pii]10.1111/j.1750-3639.2009.00337.x

243.

Wray S, Saxton M, Anderton BH, Hanger DP (2008) Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem 105:2343–2352PubMed

244.

Yamazaki M, Arai Y, Baba M et al (2000) Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 59:585–591PubMed

245.

Yokota O, Bigio EH, Ishizu H et al (2010) Phosphorylated TDP-43 accumulation in the limbic system in progressive supranuclear palsy. 111th meeting of the British Neuropathological Society. Neuropathol Appl Neurobiol 36(Suppl 1):29–30

246.

Yuan J, Xiao X, McGeehan J et al (2006) Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. J Biol Chem 281:34848–34858PubMed

247.

Zemaitaitis MO, Lee JM, Troncoso JC, Muma NA (2000) Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol 59:983–989PubMed

248.

Zetterberg H, Ruetschi U, Portelius E et al (2008) Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand 118:1–11PubMed

249.

Zou WQ, Gambetti P (2007) Prion: the chameleon protein. Cell Mol Life Sci 64:3266–3270PubMed

Title: Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics
Authors: Gabor G. Kovacs
Gergő Botond
Herbert Budka
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 4/2010
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-010-0658-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Kurt Jellinger Prize 2010 for Outstanding Scientific Writing in Neuropathology

Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2

Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis

Autopsy study of cerebellar degeneration in siblings with ataxia-telangiectasia-like disorder

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

Prevalence of dementia disorders in the oldest-old: an autopsy study